Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Antonino Mulè et al.|Journal of Clinical Oncology|2010Cited by 167
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter StudyMarco Ruella, Liliana Devizzi, Andrea Riccardo Filippi et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 48
Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Alessandro M. Gianni, Carmelo Carlo‐Stella et al.|Cancer|2011Cited by 28
BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancerFrancesca De Santis, Massimo Di Nicola|Cellular Oncology|2022Cited by 22
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose <sup>90</sup>Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAMLiliana Devizzi, Alessandro M. Gianni, Anna Guidetti et al.|Journal of Clinical Oncology|2013Cited by 14